---
title: SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological,
  Immunocompromised Patients in the Omicron Era
date: '2025-01-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39757858/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250106171058&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Our data showed that tixagevimab-cilgavimab prophylaxis
  effectively reduces severe COVID-19 outcomes in patients with HM, particularly within
  the first six months, even during the Omicron era. However, those with recent B-cell
  depletion (within 12 months) remained at high ...'
disable_comments: true
---
CONCLUSION: Our data showed that tixagevimab-cilgavimab prophylaxis effectively reduces severe COVID-19 outcomes in patients with HM, particularly within the first six months, even during the Omicron era. However, those with recent B-cell depletion (within 12 months) remained at high ...